Alector, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $251.8M
- Price
- $2.25
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.22%
- Volume
- 85.1K
About
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Quick stats
Shares outstanding111.7M
Computed float87.9M
Float / shares78.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001653087
Websitehttps://www.alector.com
AI Summary
AI-generated1/6
minorbullishearnings
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Alector reported Q2 2026 collaboration revenue of $3.3 million, down from $7.9 million in the prior year, while narrowing its net loss to $23.0 million, or $0.21 per share.
The company selected AL137 as its lead ABC-enabled anti-amyloid beta antibody program for Alzheimer's disease and targets an IND submission in Q1 2027.
With $172.8 million in cash and investments, Alector anticipates sufficient runway to fund operations at least through 2027.
Red flags
- Revenue declined 58% year-over-year due to lower collaboration revenue.
- Stockholders' equity swung to a deficit of $9.9 million from $30.6 million.